Drug Profile


Latest Information Update: 20 Mar 2008

Price : $50

At a glance

  • Originator Amgen
  • Class Metalloendopeptidases; Thrombolytics
  • Mechanism of Action Fibrinolytic agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral arterial occlusive disorders
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Catheter thrombosis; Peripheral arterial occlusive disorders; Stroke

Most Recent Events

  • 17 Mar 2008 Discontinued - Preclinical for Peripheral arterial occlusive disorders in European Union (Intra-arterial)
  • 17 Mar 2008 Discontinued - Phase-II for Stroke in Canada (Intra-arterial)
  • 17 Mar 2008 Discontinued - Phase-II for Stroke in USA (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top